Clinical Overview
Sertindole is an atypical antipsychotic with high selectivity for dopamine D2, serotonin 5-HT2A, and alpha-1 adrenergic receptors. It was withdrawn from many markets due to QT prolongation concerns but has been reintroduced in some European countries with strict monitoring requirements. It is indicated for schizophrenia but requires extensive cardiac evaluation and monitoring.
Primary Clinical Applications
Sertindole is indicated for the treatment of schizophrenia in patients who are intolerant to at least one other antipsychotic medication. Due to its cardiac safety profile, it is reserved for patients who cannot tolerate other antipsychotics and requires comprehensive cardiac assessment before and during treatment.
Mechanism and Clinical Profile
Sertindole selectively blocks dopamine D2 receptors, serotonin 5-HT2A receptors, and alpha-1 adrenergic receptors with high affinity. It has minimal activity at histamine, muscarinic, or other serotonin receptors, which may contribute to fewer side effects in some domains but also to its cardiac effects.
Safety and Monitoring Requirements
Due to significant QT prolongation risk, sertindole requires baseline ECG, electrolyte assessment, and ongoing cardiac monitoring. It is contraindicated with numerous medications and conditions that affect cardiac conduction. The medication is available only with strict monitoring protocols and is not widely available in many countries.
Prescribing Information
Dosing & Administration
Schizophrenia – Adults:
- Initial: 4 mg once daily
- Titration: Increase by 4 mg every 4-5 days
- Range: 12-24 mg once daily
- Maximum: 24 mg once daily
Restart after interruption:
- If stopped >1 week: Restart with initial titration schedule
Administration:
- Take once daily with or without food
- Same time each day
- Requires extensive cardiac monitoring
Indications
- Treatment of schizophrenia in patients intolerant to at least one other antipsychotic
- Reserved for patients who cannot tolerate other antipsychotics
Contraindications
- Hypersensitivity to sertindole
- Known QT prolongation or cardiac arrhythmias
- Clinically significant cardiac disease
- Uncorrected hypokalemia or hypomagnesemia
- Concomitant use with QT-prolonging drugs
- Severe hepatic impairment
Warnings & Precautions
- QT prolongation: Significant dose-related risk requiring ECG monitoring
- Cardiac monitoring: Baseline and periodic ECGs, electrolytes required
- Sudden death: Increased risk compared to other antipsychotics
- Neuroleptic malignant syndrome: Rare but serious risk
- Tardive dyskinesia: Risk with long-term use
- Orthostatic hypotension: Due to alpha-1 blockade
- Seizures: May lower seizure threshold
Drug Interactions
- QT-prolonging drugs: Contraindicated
- CYP3A4 inhibitors: Contraindicated (ketoconazole, macrolides)
- CYP2D6 inhibitors: Use caution, may increase sertindole levels
- Antiarrhythmics: Contraindicated
Adverse Reactions
Common (≥5%):
- Rhinitis, decreased ejaculation volume, dizziness
- Dry mouth, postural hypotension
Cardiac:
- QT prolongation (dose-related), orthostatic hypotension
Serious:
- Cardiac arrhythmias, sudden death
- Neuroleptic malignant syndrome
Special Populations
- Cardiac Disease: Contraindicated in significant cardiac disease
- Hepatic Impairment: Contraindicated in severe impairment
- Elderly: Increased mortality risk, requires careful cardiac assessment
- Pregnancy: Category C – use only if benefits outweigh risks
- Monitoring Requirements: Baseline and periodic ECGs, electrolytes, cardiac assessment
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
